Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UrtesteWAR:URT -6.91%33 Market Cap is zł65.77 Mil as of Jul. 29, 2026. GuruFocus rates WAR:URT with a GF Score™ of 33/100 and a GF Value™ of zł284.41 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 1,420 Biotechnology companies, Urteste ranks worse than 76.69% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Urteste's share price for the quarter that ended in Mar. 2026 was zł44.5. Urteste's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1.53 Mil. Therefore, Urteste's market cap for the quarter that ended in Mar. 2026 was zł67.91 Mil.
Urteste's quarterly market cap
declined
from Sep. 2025 (zł62.89 Mil) to Dec. 2025 (zł59.51 Mil) but then
increased
from Dec. 2025 (zł59.51 Mil) to Mar. 2026 (zł67.91 Mil).
Urteste's annual market cap
declined
from Dec. 2023 (zł153.69 Mil) to Dec. 2024 (zł134.23 Mil) and
declined
from Dec. 2024 (zł134.23 Mil) to Dec. 2025 (zł59.51 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Urteste's Enterprise Value for Today is zł62.79 Mil.
Urteste (WAR:URT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Urteste Market Cap Related Terms
Urteste Market Cap Historical Data
* Premium members only.
The historical data trend for Urteste's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:URT vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Urteste's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Urteste Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Urteste's Market Cap distribution charts can be found below:
* The bar in red indicates where Urteste's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Urteste's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Urteste (WAR:URT) has a Market Cap of zł65.77 Mil as of Jul. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Urteste and its competitors. According to the industry distribution chart, Urteste ranks #1089 out of 1420 companies in the Biotechnology industry, placing it in the top 76.7%.
Is Urteste's Market Cap too high?
Urteste's current Market Cap is zł65.77 Mil. Based on the distribution chart, Urteste ranks #1089 out of 1420 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Urteste has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Urteste's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Urteste ranks #1089 out of 1420 companies for Market Cap. This places Urteste in the lower half of its industry. The industry median Market Cap is 111.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.98, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Urteste and its competitors. For the Biotechnology industry, the median Market Cap is 111.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Urteste's current Market Cap is zł65.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Urteste stock overvalued right now?
Based on GuruFocus' analysis, Urteste (WAR:URT) is currently considered Possible Value Trap. The stock's GF Value™ is zł284.41, compared to a current price of zł43.10 — trading 84.8% below its estimated fair value. The current Market Cap is zł65.77 Mil. Urteste's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Urteste (WAR:URT), the current Market Cap is zł65.77 Mil as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Urteste (WAR:URT) Overvalued in 2026?
Based on GuruFocus' analysis, Urteste stock appears to be undervalued.
The current stock price of zł43.10 is trading 84.8% below its estimated GF Value™ of zł284.41.
GuruFocus considers Urteste to be Possible Value Trap.
Key valuation signals for WAR:URT:
Market Cap: zł65.77 Mil
GF Value™: zł284.41 vs. price of zł43.10 (84.8% below fair value)
No single metric tells the full story. See the WAR:URT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Urteste SA specialises in the development of technology allowing the detection of cancers at the early stages of their development. The companies technology helps detect cancers by measuring the activity of the enzymes in urine. Urteste develops diagnostic tests for more than ten common cancers.
33GF Score
Get the complete analysis for WAR:URT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:URT has been successfully added to your 
